Frelii, Inc. (OTC: FRLI), interview with CEO Ian Jenkins discussing the company’s personalized medicine technology which uses human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome.
Ian explains how Frelii is starting to commercialize it’s technology with initial applications in medical cannabis, and psychotropic medicines.
Company in position for pre-sales license inspection, last step to issuance of a Sales License FSD Pharma Inc. (“FSD Pharma” or the “Company”) (OTC: FSDDF) (cse:HUGE)(fra:0K9) is pleased to announce that its wholly-owned subsidiary, FV […]
DENVER, March 21, 2019 -Medicine Man Technologies, Inc. (otcqx:MDCL) (“Medicine Man Technologies” or “Company”), a rapidly growing, vertically integrated cannabis operator, today announced it will be presenting at the Sidoti & Company, LLC, Spring 2019 […]
BLA update and major licensing initiatives in cancer and immunology VANCOUVER, Washington, Jan 08, 2019- CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
